Chandan Taparia, derivative analyst at Anand Rathi, says Aurobindo Pharma has faced sustained selling pressure recently and the stock has fallen around 10 per cent from a support at Rs 770. No long positions are recommended until the stock sustains levels around Rs 730, he adds.
